Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
SinoMab BioScience's Sloan Ratio for the quarter that ended in Dec. 2025 was -5.56%.
As of Dec. 2025, SinoMab BioScience has a Sloan Ratio of -5.56%, indicating the company is in the safe zone and there is no funny business with accruals.
SinoMab BioScience (FRA:4VF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2025, SinoMab BioScience has a Sloan Ratio of -5.56%, indicating the company is in the safe zone and there is no funny business with accruals.
SinoMab BioScience Sloan Ratio % Related Terms
SinoMab BioScience Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4VF vs VRTX, REGN, MRNA: Sloan Ratio % Comparison
For the Biotechnology subindustry, SinoMab BioScience's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
SinoMab BioScience's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
SinoMab BioScience's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was -6.016 (Jun. 2025 ) + -6.689 (Dec. 2025 ) = €-12.71 Mil.
SinoMab BioScience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was -3.249 (Jun. 2025 ) + -5.283 (Dec. 2025 ) = €-8.53 Mil.
SinoMab BioScience's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 was 4.254 (Jun. 2025 ) + -2.301 (Dec. 2025 ) = €1.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (FRA:4VF) has a Sloan Ratio % of -5.56% as of Dec. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on SinoMab BioScience and its competitors.
Is SinoMab BioScience's Sloan Ratio % too high?
SinoMab BioScience's current Sloan Ratio % is -5.56%. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's Sloan Ratio % compare to VRTX and REGN?
SinoMab BioScience's Sloan Ratio % of -5.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on SinoMab BioScience and its competitors. SinoMab BioScience's current Sloan Ratio % is -5.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current Sloan Ratio % of -5.56%. The current Sloan Ratio % is -5.56%. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current Sloan Ratio % is -5.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
